Effect of Fixed-Dose Combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure

Inder Anand, Sithu Win, Thomas S. Rector, Jay N Cohn, Anne L. Taylor

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background-Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT). Reduction in mortality makes it difficult to determine the effect on hospitalizations unless the analysis adjusts for death as a competing risk. Methods and Results-In A-HeFT, 1050 self-identified black patients with moderate to severe HF were randomized to FDCI/ H or placebo. The effects of FDC-I/H on first and all hospitalizations and 30-day readmission rates were analyzed. Deaths as competing risks were adjusted using Fine'Gray regression and joint models of hospitalizations and mortality. There were 558 all-cause and 251 HF hospitalizations in placebo compared with 435 and 173 hospitalizations in the FDC-I/H group. Adjusting for deaths as a competing risk, the effect of FDC-I/H on the first hospitalization for HF, expressed in hazard ratio (95% confidence interval), was 0.61 (0.47'0.80; P<0.001) and 0.88 (0.72'1.06; P=0.18) on the first all-cause hospitalization. The effect of FDC-I/H on all recurrent hospitalizations for HF was 0.66 (0.52'0.83; P=0.0005), similar to the effect on the first hospitalizations for HF, whereas the effect on all hospitalizations for any cause was 0.75 (0.63'0.91; P=0.003). The 30- day all-cause readmission rate after the first hospitalization for HF was 23.6% (29 of 123) in placebo versus 14.8% (12 of 81) in the FDC-I/H group, but the effect (0.59; 0.30'1.16; P=0.12) in this small subgroup was not significant. Conclusions-Treatment with FDC-I/H was associated with a substantial reduction in the first and recurrent HF hospitalizations, and in total all-cause hospitalizations, reducing the total burden of costly and distressing hospitalizations.

Original languageEnglish (US)
Pages (from-to)759-765
Number of pages7
JournalCirculation: Heart Failure
Volume7
Issue number5
DOIs
StatePublished - Sep 1 2014

Fingerprint

Hospitalization
Heart Failure
Placebos
isosorbide-hydralazine combination
Mortality
African Americans
Joints
Confidence Intervals

Keywords

  • Heart failure
  • Hospitalization
  • Isosorbide dinitrate

Cite this

Effect of Fixed-Dose Combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure. / Anand, Inder; Win, Sithu; Rector, Thomas S.; Cohn, Jay N; Taylor, Anne L.

In: Circulation: Heart Failure, Vol. 7, No. 5, 01.09.2014, p. 759-765.

Research output: Contribution to journalArticle

@article{147698d831f2438cbfe4a245708afdb1,
title = "Effect of Fixed-Dose Combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure",
abstract = "Background-Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43{\%} and death or first hospitalization for heart failure (HF) by 37{\%} in the African-American Heart Failure Trial (A-HeFT). Reduction in mortality makes it difficult to determine the effect on hospitalizations unless the analysis adjusts for death as a competing risk. Methods and Results-In A-HeFT, 1050 self-identified black patients with moderate to severe HF were randomized to FDCI/ H or placebo. The effects of FDC-I/H on first and all hospitalizations and 30-day readmission rates were analyzed. Deaths as competing risks were adjusted using Fine'Gray regression and joint models of hospitalizations and mortality. There were 558 all-cause and 251 HF hospitalizations in placebo compared with 435 and 173 hospitalizations in the FDC-I/H group. Adjusting for deaths as a competing risk, the effect of FDC-I/H on the first hospitalization for HF, expressed in hazard ratio (95{\%} confidence interval), was 0.61 (0.47'0.80; P<0.001) and 0.88 (0.72'1.06; P=0.18) on the first all-cause hospitalization. The effect of FDC-I/H on all recurrent hospitalizations for HF was 0.66 (0.52'0.83; P=0.0005), similar to the effect on the first hospitalizations for HF, whereas the effect on all hospitalizations for any cause was 0.75 (0.63'0.91; P=0.003). The 30- day all-cause readmission rate after the first hospitalization for HF was 23.6{\%} (29 of 123) in placebo versus 14.8{\%} (12 of 81) in the FDC-I/H group, but the effect (0.59; 0.30'1.16; P=0.12) in this small subgroup was not significant. Conclusions-Treatment with FDC-I/H was associated with a substantial reduction in the first and recurrent HF hospitalizations, and in total all-cause hospitalizations, reducing the total burden of costly and distressing hospitalizations.",
keywords = "Heart failure, Hospitalization, Isosorbide dinitrate",
author = "Inder Anand and Sithu Win and Rector, {Thomas S.} and Cohn, {Jay N} and Taylor, {Anne L.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.114.001360",
language = "English (US)",
volume = "7",
pages = "759--765",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effect of Fixed-Dose Combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure

AU - Anand, Inder

AU - Win, Sithu

AU - Rector, Thomas S.

AU - Cohn, Jay N

AU - Taylor, Anne L.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background-Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT). Reduction in mortality makes it difficult to determine the effect on hospitalizations unless the analysis adjusts for death as a competing risk. Methods and Results-In A-HeFT, 1050 self-identified black patients with moderate to severe HF were randomized to FDCI/ H or placebo. The effects of FDC-I/H on first and all hospitalizations and 30-day readmission rates were analyzed. Deaths as competing risks were adjusted using Fine'Gray regression and joint models of hospitalizations and mortality. There were 558 all-cause and 251 HF hospitalizations in placebo compared with 435 and 173 hospitalizations in the FDC-I/H group. Adjusting for deaths as a competing risk, the effect of FDC-I/H on the first hospitalization for HF, expressed in hazard ratio (95% confidence interval), was 0.61 (0.47'0.80; P<0.001) and 0.88 (0.72'1.06; P=0.18) on the first all-cause hospitalization. The effect of FDC-I/H on all recurrent hospitalizations for HF was 0.66 (0.52'0.83; P=0.0005), similar to the effect on the first hospitalizations for HF, whereas the effect on all hospitalizations for any cause was 0.75 (0.63'0.91; P=0.003). The 30- day all-cause readmission rate after the first hospitalization for HF was 23.6% (29 of 123) in placebo versus 14.8% (12 of 81) in the FDC-I/H group, but the effect (0.59; 0.30'1.16; P=0.12) in this small subgroup was not significant. Conclusions-Treatment with FDC-I/H was associated with a substantial reduction in the first and recurrent HF hospitalizations, and in total all-cause hospitalizations, reducing the total burden of costly and distressing hospitalizations.

AB - Background-Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death or first hospitalization for heart failure (HF) by 37% in the African-American Heart Failure Trial (A-HeFT). Reduction in mortality makes it difficult to determine the effect on hospitalizations unless the analysis adjusts for death as a competing risk. Methods and Results-In A-HeFT, 1050 self-identified black patients with moderate to severe HF were randomized to FDCI/ H or placebo. The effects of FDC-I/H on first and all hospitalizations and 30-day readmission rates were analyzed. Deaths as competing risks were adjusted using Fine'Gray regression and joint models of hospitalizations and mortality. There were 558 all-cause and 251 HF hospitalizations in placebo compared with 435 and 173 hospitalizations in the FDC-I/H group. Adjusting for deaths as a competing risk, the effect of FDC-I/H on the first hospitalization for HF, expressed in hazard ratio (95% confidence interval), was 0.61 (0.47'0.80; P<0.001) and 0.88 (0.72'1.06; P=0.18) on the first all-cause hospitalization. The effect of FDC-I/H on all recurrent hospitalizations for HF was 0.66 (0.52'0.83; P=0.0005), similar to the effect on the first hospitalizations for HF, whereas the effect on all hospitalizations for any cause was 0.75 (0.63'0.91; P=0.003). The 30- day all-cause readmission rate after the first hospitalization for HF was 23.6% (29 of 123) in placebo versus 14.8% (12 of 81) in the FDC-I/H group, but the effect (0.59; 0.30'1.16; P=0.12) in this small subgroup was not significant. Conclusions-Treatment with FDC-I/H was associated with a substantial reduction in the first and recurrent HF hospitalizations, and in total all-cause hospitalizations, reducing the total burden of costly and distressing hospitalizations.

KW - Heart failure

KW - Hospitalization

KW - Isosorbide dinitrate

UR - http://www.scopus.com/inward/record.url?scp=84925863921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925863921&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.114.001360

DO - 10.1161/CIRCHEARTFAILURE.114.001360

M3 - Article

VL - 7

SP - 759

EP - 765

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 5

ER -